The Peptide Field. Bremelanotide: approval and evidence record.

Editorial review: 2026-08-01. Dataset version: 2026-09-11.1.

https://thepeptidefield.com/peptides/bremelanotide

Lookup: https://thepeptidefield.com/peptide-evidence-checker?peptide=bremelanotide#result

This is a dated editorial summary, not a live FDA check or independent medical review. It does not recommend treatment or verify a product in hand.

Status: An FDA-approved product exists for a narrow indication

Exact product limits: Evidence for Vyleesi does not automatically apply to every PT-141 product. Vyleesi is an approved, product-specific presentation. Calling any PT-141 product 'Vyleesi' or transferring its evidence to compounded material is not justified.

Human outcomes: Moderate. Two phase 3 trials support modest changes in prespecified desire and distress endpoints for the labeled population.

Body effects in people: Strong. Exposure and transient cardiovascular effects are characterized in the approved label.

What the evidence shows: The RECONNECT phase 3 trials reported improvements in planned measures of desire and distress in premenopausal women with acquired, generalized HSDD. HSDD is a diagnosed form of low sexual desire. The label says it is not indicated to enhance sexual performance.

What remains unknown: The evidence does not establish treatment of all causes of low desire, benefit in men or postmenopausal women, a relationship benefit for everyone, or equivalence of compounded PT-141.

Safety limits: The label says the product must not be used with uncontrolled hypertension or known cardiovascular disease. It also describes temporary blood-pressure increases. This guide provides no dosing or injection advice.

Product record: Vyleesi. Form: Single-dose autoinjector. Route: Subcutaneous.
Scope: Acquired, generalized hypoactive sexual desire disorder in the premenopausal population and circumstances defined in the label.
Published label: September 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf

Approval claim: “Bremelanotide is FDA-approved for a specific form of HSDD.”
Verdict: Supported with scope. Vyleesi is approved for acquired, generalized HSDD in certain premenopausal women after specified exclusions.
Evidence basis: Regulatory or product record. Scope: The population and limitations in the current Vyleesi label.
Claim sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf

Sources used in the full review (a source is not support for every claim):

U.S. Food and Drug Administration. VYLEESI (bremelanotide) prescribing information. 2020. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210557s002lbl.pdf

PubMed · Obstetrics & Gynecology. Bremelanotide for HSDD: two randomized phase 3 trials. 2019. Accessed 2026-07-23. https://pubmed.ncbi.nlm.nih.gov/31599840/

U.S. Food and Drug Administration. Vyleesi multidisciplinary review. 2019. Accessed 2026-07-23. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000MultidisciplineR.pdf

Keep the limits, review date, and sources with this record. Check the current source for changes.